In This Article:
As global markets continue to reach record highs, driven by positive economic indicators and geopolitical developments, investors are navigating a complex landscape marked by both opportunities and uncertainties. Amidst this environment, identifying stocks that may be priced below their estimated value can offer potential for growth, particularly when broader market sentiment is buoyant.
Top 10 Undervalued Stocks Based On Cash Flows
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| NBT Bancorp (NasdaqGS:NBTB) | US$50.12 | US$99.93 | 49.8% |
| Giant Biogene Holding (SEHK:2367) | HK$48.30 | HK$96.33 | 49.9% |
| PharmaResearch (KOSDAQ:A214450) | ₩213500.00 | ₩425786.18 | 49.9% |
| Stille (OM:STIL) | SEK220.00 | SEK437.81 | 49.7% |
| Power Root Berhad (KLSE:PWROOT) | MYR1.46 | MYR2.92 | 50% |
| EnomotoLtd (TSE:6928) | ¥1460.00 | ¥2918.40 | 50% |
| Mobvista (SEHK:1860) | HK$8.55 | HK$15.99 | 46.5% |
| EQL Pharma (OM:EQL) | SEK77.00 | SEK153.58 | 49.9% |
| Sands China (SEHK:1928) | HK$20.30 | HK$40.57 | 50% |
| Hesai Group (NasdaqGS:HSAI) | US$8.18 | US$16.30 | 49.8% |
Here we highlight a subset of our preferred stocks from the screener.
PharmaResearch
Overview: PharmaResearch Co., Ltd., along with its subsidiaries, is a biopharmaceutical company operating mainly in South Korea, with a market cap of ₩2.06 trillion.
Operations: PharmaResearch Co., Ltd. and its subsidiaries focus on the biopharmaceutical sector, primarily serving the South Korean market.
Estimated Discount To Fair Value: 49.9%
PharmaResearch appears undervalued, trading at 49.9% below its estimated fair value of ₩425,786.18. Despite a recent private placement raising nearly ₩200 billion, the company's earnings are forecast to grow significantly at 27.94% annually, although slightly slower than the market average. Revenue growth is expected to outpace the KR market substantially at 24.2% per year. Analysts agree on a potential stock price rise of 32.4%, highlighting its strong relative value compared to peers and industry standards.
Sands China
Overview: Sands China Ltd. develops, owns, and operates integrated resorts and casinos in Macao with a market cap of HK$160.57 billion.
Operations: The company's revenue segments include The Venetian Macao at $2.93 billion, The Londoner Macao at $2.11 billion, The Parisian Macao at $961 million, The Plaza Macao at $776 million, Sands Macao at $319 million, and Ferry and Other Operations contributing $109 million.